Cargando…
Strategies to Inhibit Myc and Their Clinical Applicability
Myc is an oncogene deregulated in most—perhaps all—human cancers. Each Myc family member, c-, L-, and N-Myc, has been connected to tumor progression and maintenance. Myc is recognized as a “most wanted” target for cancer therapy, but has for many years been considered undruggable, mainly due to its...
Autores principales: | Whitfield, Jonathan R., Beaulieu, Marie-Eve, Soucek, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322154/ https://www.ncbi.nlm.nih.gov/pubmed/28280720 http://dx.doi.org/10.3389/fcell.2017.00010 |
Ejemplares similares
-
The long journey to bring a Myc inhibitor to the clinic
por: Whitfield, Jonathan R., et al.
Publicado: (2021) -
Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein
por: Beaulieu, Marie-Eve, et al.
Publicado: (2020) -
Targeting MYC-driven lymphoma: lessons learned and future directions
por: Martínez-Martín, Sandra, et al.
Publicado: (2023) -
MYC and AMPK–Save Energy or Die!
por: Haikala, Heidi M., et al.
Publicado: (2017) -
In vivo Reprogramming of Cancer Metabolism by MYC
por: Camarda, Roman, et al.
Publicado: (2017)